The influence of exogenous progestin on the occurrence of proestrous or estrous signs, plasma concentrations of luteinizing hormone and estradiol in deslorelin (GnRH agonist) treated anestrous bitches.
The objectives of this study were to confirm: (i) whether progestin treatment suppressed GnRH agonist-induced estrus in anestrous greyhound bitches; and (ii) the site of progestin action (i.e. pituitary, ovary). All bitches received a deslorelin implant on Day 0 and blood samples were taken from -1 h to +6 h. Five bitches were treated with megestrol acetate (2 mg/kg orally once daily) from -7 d to +6 d (Group 1) and 10 bitches were untreated controls (Group 2). Proestrous or estrous signs were observed in 4 of 5 bitches in Group 1, and 4 of 10 bitches in Group 2 (P = 0.28). The plasma LH responses (area under the curve from 0 to 6h after implantation) were higher (P = 0.008) in Group 2 than in Group 1. Plasma LH responses were similar (P = 0.59) in bitches showing signs of proestrus or estrus (responders) and in non-responders. The plasma estradiol responses (calculated as for LH response) were greater in Group 1 than in Group 2 (P = 0.048), and in responders than in non-responders (P = 0.02).


CONCLUSIONS
(i) progestin treatment (a) did not suppress the incidence of bitches showing deslorelin-induced proestrus or estrus, and (b) was associated with a reduced pituitary responsiveness and an increased ovarian responsiveness to deslorelin treatment; (ii) the occurrence of proestrous or estrous signs reflected increased ovarian responsiveness to induced gonadotrophin secretion and not increased pituitary responsiveness to deslorelin.
Sung
M
M
Department of Veterinary Science, The University of Melbourne, Werribee, Vic. 3030, Australia. gingkobean@yahoo.com
Armour
A F
AF
Wright
P J
PJ
D000780:Anestrus / Q000187:drug effects / Q000502:physiology*; D000818:Animals; D004285:Dogs / Q000097:blood / Q000502:physiology*; D004343:Drug Implants; D004958:Estradiol / Q000097:blood*; D004971:Estrus / Q000187:drug effects / Q000502:physiology; D005260:Female; D007986:Luteinizing Hormone / Q000097:blood*; D019290:Megestrol Acetate / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D011372:Progestins / Q000494:pharmacology*; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology
D004343:Drug Implants; D011372:Progestins; D017329:Triptorelin Pamoate; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D019290:Megestrol Acetate; C066438:deslorelin